Suven Life Sciences Aims At 15-20% Topline Growth In FY20
  • WebDesk BTVI
  • Aug 20 2019

Biopharmaceutical company Suven Life Sciences posted a flat profit growth in June quarter at Rs 26.2 crore, while its revenues rose marginally to Rs 198.98 crore from Rs 191.6 crore. Speaking to BTVI, Venkat Jasti, Chairman & CEO, Suven Life Sciences, said the firm expects robust growth in the coming quarters. It is planning to demerge Suven Life and Suven Pharma and list them. Jasti is aiming at a topline growth of 15-20 per cent for FY20. Here's more.